oral glp-1 agonists GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies New GLP-1 Guidelines for Type
Description
h - p , Glucose-stimulated insulin secretion
Find out | JAMA
Pediatric and Adolescent Obesity Treatment: Since FDA approval in 2022, GLP-1 receptor agonists have been prescribed for individuals aged 12 years and older with obesity (BMI 95th percentile)
These dual agonists were found to reduce blood sugar and increase insulin secretion in mice, monkeys, and humans
doi: 10.1186/s12902-021-00908-1 121 ShuaiYYangGZhangQLiWLuoYMaJet al
